{"entity":{"id":"scancell","kind":"company","name":"Scancell","aka":["Scancell Ltd"],"tldr":"Scancell is a United Kingdom-based biotechnology company running 2 late-stage cancer trials in melanoma, triple-negative breast cancer and renal cell carcinoma.","summary":"Scancell, based in Oxford, the United Kingdom, is a biotechnology company. Scancell is a late-stage clinical company developing active immunotherapies designed to enhance anti-tumour immune responses in cancer. On ClinicalTrials.gov it is the lead sponsor of 2 recruiting or active phase 2 and phase 3 interventional cancer trials in melanoma, triple-negative breast cancer, renal cell carcinoma, ovarian cancer and head and neck squamous cell carcinoma. The largest, NCT04079166 (SCIB1 and iSCIB1+ in Melanoma Patients Receiving Nivolumab With Ipilimumab or SCIB1 With Pembrolizumab (The SCOPE Study)), plans to enrol 173 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.scancell.co.uk/"},{"label":"ClinicalTrials.gov: trials led by Scancell","url":"https://clinicaltrials.gov/search?lead=Scancell%20Ltd"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["melanoma","tnbc","rcc","ovarian","head-and-neck"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct05329532","nct04079166"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Oxford","country":"GB","companyType":"biotech","website":"https://www.scancell.co.uk/","founded":1996,"stage":"public","investors":[],"funding":[]},"route":"/companies/scancell/","neighbours":{"cancer":[{"id":"head-and-neck","kind":"cancer","name":"Head and neck squamous cell carcinoma","route":"/cancers/head-and-neck/"},{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"},{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"},{"id":"rcc","kind":"cancer","name":"Renal cell carcinoma","route":"/cancers/rcc/"},{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/"}],"trial":[{"id":"nct05329532","kind":"trial","name":"Modi-1 Moditope in Breast, Head and Neck, Ovarian, or Renal Cancer","route":"/trials/nct05329532/"},{"id":"nct04079166","kind":"trial","name":"SCIB1 and iSCIB1+ in Melanoma Patients Receiving Nivolumab With Ipilimumab or SCIB1 With Pembrolizumab (The SCOPE Study)","route":"/trials/nct04079166/"}]}}